The Medication Myth Your Doctor Isn't Allowed to Tell You: Why Your Prescription is Only Half the Story
You leave the doctor's office with a script in hand, a plan in mind, and hope for a cure. You take the pill faithfull...
TREANDA INJECTION 100mg (Bendamustine Hydrochloride)
$1,456.67
Active Ingredient : Bendamustine Hydrochloride
TREANDA INJECTION 100mg (Bendamustine Hydrochloride) is an effective treatment option for patients with certain types of cancer, offering a targeted approach to chemotherapy that helps improve patient outcomes.
Reliable shipping
Flexible returns
Dispensing Country : India
TREANDA Injection 100mg, containing Bendamustine Hydrochloride, is a chemotherapy medication primarily used to treat certain types of cancer, including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). It belongs to the class of alkylating agents, which work by interfering with the DNA replication process in cancer cells, thereby inhibiting their growth and proliferation.
This medication is administered intravenously under the supervision of a healthcare professional. The dosage and treatment schedule are determined based on the patient’s condition, body surface area, and response to therapy. TREANDA is often prescribed when other treatments have not been effective or are unsuitable for the patient.
Patients receiving TREANDA Injection may experience side effects, which can range from mild to severe. Common side effects include nausea, fatigue, fever, and low blood cell counts. More serious side effects, such as infections, allergic reactions, or liver problems, may also occur and require immediate medical attention.
- Indications: Treatment of CLL and NHL.
- Mechanism of Action: Alkylating agent that disrupts DNA replication in cancer cells.
- Administration: Intravenous infusion under medical supervision.
- Common Side Effects: Nausea, fatigue, fever, and low blood cell counts.
- Precautions: Regular monitoring of blood counts and liver function is essential during treatment.
It is crucial for patients to inform their healthcare provider about any pre-existing medical conditions or medications they are taking, as TREANDA may interact with other drugs or exacerbate certain health issues. Pregnant or breastfeeding women should avoid this medication due to potential risks to the fetus or infant.
TREANDA Injection has shown significant efficacy in improving outcomes for patients with CLL and NHL, making it a valuable option in the management of these cancers. However, its use requires careful consideration of the patient’s overall health and close monitoring to minimize risks and maximize benefits.
- Bendamustine Hydrochloride
- Mannitol
- Hydrochloric Acid
- Sodium Hydroxide
- Water for Injection
TREANDA INJECTION 100mg (Bendamustine Hydrochloride) is a prescription medication used primarily for the treatment of certain types of cancer, including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). It is administered intravenously and should only be used under the supervision of a healthcare professional experienced in cancer chemotherapy.
Before administering TREANDA, ensure that the patient’s blood counts, liver function, and kidney function are evaluated. This medication can cause myelosuppression, so it is crucial to monitor blood counts regularly during treatment. TREANDA should be reconstituted and diluted as per the instructions provided by the manufacturer or the healthcare provider.
- Reconstitute the 100mg vial with 20mL of sterile water for injection. Gently swirl the vial until the powder is completely dissolved. The resulting solution will have a concentration of 5mg/mL.
- Dilute the reconstituted solution further in 500mL of 0.9% sodium chloride injection or 2.5% dextrose/0.45% sodium chloride injection. The final concentration should be within the recommended range for safe administration.
- Administer the diluted solution intravenously over a period of 30 minutes. The infusion time may vary based on the patient’s condition and the healthcare provider’s instructions.
- Monitor the patient for any adverse reactions during and after the infusion. Common side effects include nausea, vomiting, fatigue, fever, and low blood cell counts. Severe reactions such as allergic responses or infections should be addressed immediately.
The typical dosage of TREANDA depends on the type of cancer being treated. For CLL, the recommended dose is 100mg/m² administered on days 1 and 2 of a 28-day cycle, up to 6 cycles. For NHL, the dose is 120mg/m² on days 1 and 2 of a 21-day cycle, for up to 8 cycles. Adjustments may be necessary based on the patient’s tolerance and clinical response.
Store TREANDA vials at controlled room temperature, protected from light. Unopened vials should be kept in their original packaging until ready for use. Once reconstituted, the solution should be used immediately or stored in a refrigerator for up to 24 hours. Discard any unused solution appropriately.
Patients should be advised to report any signs of infection, unusual bleeding, or severe side effects to their healthcare provider. TREANDA may interact with other medications, so it is important to inform the healthcare team of all drugs, supplements, or herbal products the patient is taking.
You may also like
Our products are sourced directly from brands or authorized distributors.
